FDA reverses decision not to review Moderna’s new – Business News
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company mentioned Wednesday.
Last week, the FDA despatched a missive to Moderna refusing to review its new shot, saying its utility did not comprise sufficient analysis – leaving the company’s president Dr. Stephen Hoge in “complete shock.”
Moderna’s flu vaccine will not be reviewed by the FDA. Rawf8 – stock.adobe.com
In an unique interview with The Post, Hoge mentioned he was “completely surprised and honestly pretty confused” after receiving the letter from Dr. Vinay Prasad.
The security company’s reversal follows The Post’s editorial warning that blocking the final stage of approval for the vaccine might finally kill “hundreds, maybe thousands, of senior citizens.”
The FDA will not review Moderna’s new flu vaccine. REUTERS
Moderna proposed a break up utility to pace alongside the review, looking for full approval for adults aged 50 to 64 and accelerated approval for these 65 and older – contingent on conducting a examine amongst older adults after the vaccine’s release.
The FDA has set an August deadline to determine whether or not to approve the new vaccine, in accordance to Moderna. If authorized, seniors shall be ready to roll up their sleeves for the new jab in time for the 2026-2027 flu season.
